APGOT own trials

APGOT own trials

A multicenter phase II randomized trial of durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas, MOCCA.

ClinicalTrials.gov Identifier: NCT03899610.GO TO LINK

Detailed study information is available at

PMID: 31576697GO TO LINK

DOI: 10.3802/jgo.2019.30.e112GO TO LINK

doenload pdf

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.

ClinicalTrials.gov Identifier: NCT03699449.GO TO LINK

Detailed study information is available at

PMID: 31671191GO TO LINK

DOI: 10.1093/jjco/hyz085GO TO LINK

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer, OPEB-01 (APGOT OV4).

ClinicalTrials.gov Identifier: NCT04361370.GO TO LINK

Detailed study information is available at

PMID: 33559413GO TO LINK

DOI: 10.3802/jgo.2021.32.e31GO TO LINK

doenload pdf

A multicenter phase II trial of lenvatinib plus pembrolizumab in recurrent gynecological clear cell adenocarcinomas, LARA (APGOT OV3).

ClinicalTrials.gov Identifier: NCT04699071.GO TO LINK

Detailed study information is available at

doenload pdf